SC 13G 1 edgewisetherapeutics13g.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No. ___)

Edgewise Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

28036F105

(CUSIP Number)

September 14, 2022

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[X] Rule 13d-1(b)

[X] Rule 13d-1(c)

[ ] Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

CUSIP No. 28036F105

Names of Reporting Persons.

EcoR1 Capital, LLC

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a) X

(b)

SEC Use Only

Citizenship or Place of Organization Delaware

Number of Shares Beneficially Owned by Each Reporting Person With:	5. Sole Voting Power -0-
	6. Shared Voting Power 3,493,194
	7. Sole Dispositive Power -0-
	8. Shared Dispositive Power 3,493,194

Aggregate Amount Beneficially Owned by Each Reporting Person 3,493,194

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

11.

Percent of Class Represented by Amount in Row (9) 5.5%

12.

Type of Reporting Person (See Instructions) OO, IA

CUSIP No. 28036F105

Names of Reporting Persons.

Oleg Nodelman

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a) X

(b)

SEC Use Only

Citizenship or Place of Organization United States

Number of Shares Beneficially Owned by Each Reporting Person With:	5. Sole Voting Power -0-
	6. Shared Voting Power 3,493,194
	7. Sole Dispositive Power -0-
	8. Shared Dispositive Power 3,493,194

Aggregate Amount Beneficially Owned by Each Reporting Person 3,493,194

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

11.

Percent of Class Represented by Amount in Row (9) 5.5%

12.

Type of Reporting Person (See Instructions) IN, HC

CUSIP No. 28036F105

Names of Reporting Persons.

EcoR1 Capital Fund Qualified, L.P.

Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ______

(b) ______

3. SEC Use Only

Citizenship or Place of Organization Delaware

Number of Shares Beneficially Owned by Each Reporting Person With:	5. Sole Voting Power -0-
	6. Shared Voting Power 3,290,460
	7. Sole Dispositive Power -0-
	8. Shared Dispositive Power 3,290,460

Aggregate Amount Beneficially Owned by Each Reporting Person 3,290,460

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
Instructions) ______

11.

Percent of Class Represented by Amount in Row (9) 5.2%

12.

Type of Reporting Person (See Instructions) PN

CUSIP No. 28036F105

Item

(a)

Name of Issuer

Edgewise Therapeutics, Inc.

(b)

Address of Issuer’s Principal Executive Offices

3415 Colorado Ave, Boulder, Colorado 80303

________________________________________________________________________

Item

(a)

The names of the persons filing this statement are:

EcoR1 Capital Fund Qualified, L.P. (“Qualified Fund”); EcoR1 Capital, LLC (“EcoR1”) and Oleg Nodelman (“Nodelman”) (collectively, the “Filers”).

Qualified Fund is filing this statement jointly with the other Filers, but not as a member of a group and it expressly disclaims membership in a group. In addition, filing this Schedule 13G on behalf of Qualified Fund should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any of the Stock covered by this Schedule 13G.

Each Filer also disclaims beneficial ownership of the Stock except to the extent of that person’s pecuniary interest therein.

(b)

The principal business office of the Filers is located at:

357 Tehama Street #3, San Francisco, CA 94103

(c)

For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

(d)

This statement relates to the Issuer’s shares of Common Stock, par value $0.0001 per share (the “Stock”).

(e)

The CUSIP number of the Issuer is: 28036F105.

CUSIP No. 28036F105

Item 3.

If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b)

[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c)

[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d)

[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e)

[ X ] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E) as to EcoR1.

(f)

[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).

(g)

[ X ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G)
as to Mr. Nodelman.

(h)

[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

(i)

[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

(j)

[ ] Group, in accordance with section 240.13d-1(b)(1)(ii)(J).

Item 4.

Ownership.

See Items 5-9 and 11 of the cover page for each Filer.

The percentages reported in this Schedule 13G are based on 63,152,458 shares of the Issuer’s Common Stock outstanding after the closing of the offering of shares by the Issuer on September 16, 2022, and assuming the full exercise of the underwriter’s option to purchase additional shares, as reported in the prospectus filed by the Issuer on September 14, 2022.

Item 5.

Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not applicable.

Item 8.

Identification and Classification of Members of the Group.

EcoR1 is the general partner and investment adviser of investment funds, including Qualified Fund. Mr. Nodelman is the control person of EcoR1.

Item 9.

Notice of Dissolution of Group.

Not applicable.

Item 10.

Certification.

Certification of EcoR1 and Mr. Nodelman:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

Certification of Qualified Fund:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: September 26, 2022

EcoR1 CAPITAL, LLC

By:/s/ Oleg Nodelman

Oleg Nodelman, Manager

/s/ Oleg Notelman
Oleg Nodelman

EcoR1 CAPITAL FUND QUALIFIED, L.P.

By: EcoR1 Capital, LLC, General Partner

By:/s/ Oleg Nodelman

Oleg Nodelman, Manager

CUSIP No. 28036F105

EXHIBIT A

AGREEMENT REGARDING JOINT FILING
OF STATEMENT ON SCHEDULE 13D OR 13G

The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D, Schedule 13G or Forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) or 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint EcoR1 Capital, LLC a Delaware limited liability company, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

Dated: September 26, 2022

EcoR1 CAPITAL, LLC

By:/s/ Oleg Nodelman

Oleg Nodelman, Manager

/s/ Oleg Nodelman
Oleg Nodelman

EcoR1 CAPITAL FUND QUALIFIED, L.P.

By: EcoR1 Capital, LLC, General Partner

By:/s/ Oleg Nodelman

Oleg Nodelman, Manager

08689\007\9327549.v2

SEC Form SC 13G filed by Edgewise Therapeutics Inc.